Safer, faster workflows start with technology that clinicians actually want to use. This blog explores how IQHT builds iQemo in close partnership with oncology teams, using real user insights shared at BOPA to drive design verification, ongoing research, and AI-driven clinical decision support. Ready to help shape the future of SACT prescribing? Read more and join our National Horizons Panel.
Read moreSign-up to the newsletter
We are very pleased to report the next successful iQemo activation within SA Health at Lyell McEwin Hospital, Adelaide, South Australia
Read more
iQHealthTech in collaboration with Altera Digital Health in Australia have celebrated the successful go-live of iQemo at Mount Gambier and Districts Health Service!
Read more
Biosimilar switching is becoming more common as Rituximab, Trastuzumab and Bevacizumab all have biosimilars on the market. Due to stock shortages and contract prices, there may be a need to switch biosimilars more regularly. This will become more common as additional biosimilar products come to the market. iQemo can facilitate biosimilar switching through several mechanisms.
Read more
Beyond the standard benefits of e-prescribing, iQemo provides many additional features that will help your organisation further improve the safety of its patients receiving chemotherapy.
Read more
An explanation of the iQemo settings hierarchy, from drug-formulary to drug-level, and how that relates to dose capping.
Read more
Research by members of BOPA uncovers the clear need to streamline, standardise and share regimens across a national library.
Read more
Enhancing patient safety and reducing the burdens on clinical staff, with end-to-end administration tracking through label printing and barcode scanning support in the iQemo prescribing platform.
Read moreSign up to our newsletter and stay updated with industry-leading advice, insight and more…